John Oyler, BeiGene CEO (Endpoints News, PharmCube)

BeiGene dives in on nat­ur­al killer cells with dis­cov­ery pact for small biotech's stem cell-based plat­form

Chi­na’s BeiGene has been busy on the on­col­o­gy front in re­cent years, look­ing to keep up with the pack with one late-stage PD-1 on the way to a fil­ing and a slate of small deals flesh­ing out the pipeline. Now, with its eyes on the hori­zon, the drug­mak­er has snared an ear­ly-stage pact for a clutch of next-gen cell ther­a­pies.

BeiGene will shell out $45 mil­lion in cash and an undis­closed amount in fu­ture biobucks and roy­al­ties for up to four of Shore­line Bio­sciences’ in­duced pluripo­tent stem cell-based nat­ur­al killer ther­a­pies for can­cer, the part­ners said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.